Lucy Therapeutics logo

Lucy Therapeutics jobs and careers

Cambridge, MA, United States

About Lucy Therapeutics

Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Founded in 2017 by Amy Ripka.

Founded
2017
Employees
11 to 50
Total funding
$38.5M
Headquarters
Cambridge

Leadership

The top of Lucy Therapeutics's org chart, with how many people report into each leader.

ARPhoto of Amy Ripka

Amy Ripka

CEO

4 reports

AHPhoto of Allen Hopper

Allen Hopper

VP Drug Discovery

2 reports

BKPhoto of Bryan Keaney

Bryan Keaney

Chief Financial Officer

Board

ADPhoto of Ann DeWitt

Ann DeWitt

Director

JR

John Ripple

Independent Director

JBPhoto of Joanne Bronson

Joanne Bronson

Scientific Advisor

PLPhoto of Peter Lansbury

Peter Lansbury

Scientific Advisor

GMPhoto of Giovanni Manfredi

Giovanni Manfredi

Scientific Advisor

JMPhoto of John Macor

John Macor

Scientific Advisor